CN101056890B - 脱酰胺基干扰素-β - Google Patents

脱酰胺基干扰素-β Download PDF

Info

Publication number
CN101056890B
CN101056890B CN2005800381182A CN200580038118A CN101056890B CN 101056890 B CN101056890 B CN 101056890B CN 2005800381182 A CN2005800381182 A CN 2005800381182A CN 200580038118 A CN200580038118 A CN 200580038118A CN 101056890 B CN101056890 B CN 101056890B
Authority
CN
China
Prior art keywords
ifn
protein
deamidated
beta
interferon
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2005800381182A
Other languages
English (en)
Chinese (zh)
Other versions
CN101056890A (zh
Inventor
古谷健二
D·约翰逊-杰克逊
D·T·鲁斯西奥
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of CN101056890A publication Critical patent/CN101056890A/zh
Application granted granted Critical
Publication of CN101056890B publication Critical patent/CN101056890B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2005800381182A 2004-11-10 2005-11-10 脱酰胺基干扰素-β Expired - Fee Related CN101056890B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62683704P 2004-11-10 2004-11-10
US60/626,837 2004-11-10
PCT/US2005/040758 WO2006053134A2 (en) 2004-11-10 2005-11-10 Deamidated interferon-beta

Publications (2)

Publication Number Publication Date
CN101056890A CN101056890A (zh) 2007-10-17
CN101056890B true CN101056890B (zh) 2012-05-09

Family

ID=36337216

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2005800381182A Expired - Fee Related CN101056890B (zh) 2004-11-10 2005-11-10 脱酰胺基干扰素-β

Country Status (16)

Country Link
US (2) US7595040B2 (https=)
EP (1) EP1809662B1 (https=)
JP (1) JP4891250B2 (https=)
KR (1) KR101330626B1 (https=)
CN (1) CN101056890B (https=)
AT (1) ATE415421T1 (https=)
AU (1) AU2005304486B2 (https=)
BR (1) BRPI0517697A (https=)
CA (1) CA2587061C (https=)
DE (1) DE602005011321D1 (https=)
ES (1) ES2318575T3 (https=)
MX (1) MX2007004990A (https=)
PL (1) PL1809662T3 (https=)
PT (1) PT1809662E (https=)
RU (1) RU2404190C2 (https=)
WO (1) WO2006053134A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
CN101506232A (zh) * 2006-08-08 2009-08-12 诺瓦提斯公司 具有增强的生物活性的重组干扰素-β
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
EP2207890A4 (en) * 2007-10-05 2010-12-15 Barofold Inc HIGH PRESSURE PROCESSING OF AGGREGATED INTERFERONS
CN106132983B (zh) * 2014-04-04 2021-03-26 阿雷斯贸易股份有限公司 新型IFN-β蛋白类似物
RU2739261C1 (ru) * 2019-12-31 2020-12-22 Федеральное государственное бюджетное учреждение науки институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова Российской академии наук (ИБХ РАН) Способ количественного определения антипролиферативной активности интерферона-бета человека

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588585A (en) 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
TR199901968T2 (xx) 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
US20030190307A1 (en) 1996-12-24 2003-10-09 Biogen, Inc. Stable liquid interferon formulations
US6696423B1 (en) 1997-08-29 2004-02-24 Biogen, Inc. Methods and compositions for therapies using genes encoding secreted proteins such as interferon-beta
EP1426058A3 (de) * 1997-09-23 2004-07-28 Dr. Rentschler Biotechnologie GmbH Flüssige Interferon-Beta Formulierungen
ATE488529T1 (de) 1999-07-28 2010-12-15 Genentech Inc Zusammensetzungen und verfahren zur behandlung von tumoren
ES2180416B1 (es) 2001-03-12 2004-06-01 BIOTOOLS BIOTECHNOLOGICAL & MEDICAL LABORATORIES, S.A. Procedimiento para la preparacion de mezclas de reaccion estabilizadas, total o parcialmente desecadas, que comprenden, al menos, una enzima, mezclas de reaccion y kits que las contienen.
AR034749A1 (es) * 2001-07-09 2004-03-17 Schering Ag Formulaciones de interferon beta humano
RU2216345C1 (ru) * 2002-03-21 2003-11-20 Закрытое Акционерное Общество "Биокад" Средство, обладающее иммуномодулирующим, противовирусным, противобактериальным, регенерирующим, репаративным, мембрано- и гепатопротекторным действием
KR100541850B1 (ko) 2003-03-31 2006-01-11 삼성정밀화학 주식회사 인간 인터페론-베타 변이체 및 그의 제조방법

Also Published As

Publication number Publication date
CN101056890A (zh) 2007-10-17
RU2404190C2 (ru) 2010-11-20
US20060120998A1 (en) 2006-06-08
KR101330626B1 (ko) 2013-11-18
WO2006053134A2 (en) 2006-05-18
CA2587061C (en) 2011-08-16
RU2007121515A (ru) 2008-12-20
ATE415421T1 (de) 2008-12-15
JP2008519769A (ja) 2008-06-12
KR20070084559A (ko) 2007-08-24
AU2005304486B2 (en) 2011-08-11
EP1809662A2 (en) 2007-07-25
BRPI0517697A (pt) 2008-10-14
PL1809662T3 (pl) 2009-07-31
MX2007004990A (es) 2007-06-14
JP4891250B2 (ja) 2012-03-07
US20090263355A1 (en) 2009-10-22
DE602005011321D1 (de) 2009-01-08
AU2005304486A1 (en) 2006-05-18
EP1809662B1 (en) 2008-11-26
US7595040B2 (en) 2009-09-29
PT1809662E (pt) 2009-02-26
CA2587061A1 (en) 2006-05-18
ES2318575T3 (es) 2009-05-01
WO2006053134A3 (en) 2006-08-31

Similar Documents

Publication Publication Date Title
US4929554A (en) Human immune interferon
US5382658A (en) Stability-enhanced variants of parathyroid hormone
JPH06502987A (ja) Ｏ―グリコシル化ｉｆｎ―アルファ
US20090263355A1 (en) Deamidated interferon-beta
BG107844A (bg) Методи за пречистване и регенерация на протеин
US20090311216A1 (en) Recombinant interferon-beta with enhanced biological activity
JP2000505079A (ja) 肥満症タンパク質製剤
IE914484A1 (en) Oxidation resistant variants of parathyroid hormone
CN101341169B (zh) Fsh突变体
EP0796276B1 (en) Gradual modification, super-agonists and antagonists of signal-proteins and peptides
CA2256368A1 (en) An interleukin-5 antagonist
AU723413B2 (en) An interleukin-5 antagonist
Kao et al. Expression of a 72-kDa major allergen of American cockroach in hybridoma cell Sp2/0-Ag14
Lin et al. and Maninder S. Hora
JPS62223200A (ja) 新規な生理活性ペプチド
JPH0482900A (ja) 新規ｍ―ｃｓｆ及びその製造方法
DD264706A5 (de) Verfahren zur Herstellung von Polypeptiden (Pferde-Interforon-Gamma)

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20120509

Termination date: 20151110

EXPY Termination of patent right or utility model